Please ensure Javascript is enabled for purposes of website accessibility

4 Biotechs' Dominant Moves

By Dave Williamson – Nov 13, 2012 at 2:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A closer look at today's big market movers

In this video, Motley Fool health care analyst David Williamson gives us the story behind two big biotech jumps today and two big stumbles. Sequenom (NASDAQ: SQNM) continues its rally from Friday with more good news that its RetnaGene AMD accurately predicts the progression of wet age-related macular degeneration; this has shares up an additional 8% on top of Friday's 19%. Repros Therapeutics (NASDAQ: RPRX) also up today ahead of presenting both of its phase 2 drugs, Androxal and Proellex, at the Lazard conference tomorrow. Meanwhile, Cyclacel (NASDAQ: CYCC) and Transcept (NASDAQ: TSPT) are both down today after disappointing earnings releases.

David Williamson has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cyclacel Pharmaceuticals, Inc. Stock Quote
Cyclacel Pharmaceuticals, Inc.
CYCC
$1.32 (-3.65%) $0.05
Paratek Pharmaceuticals, Inc. Stock Quote
Paratek Pharmaceuticals, Inc.
PRTK
$2.51 (1.21%) $0.03
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$691.82 (-1.93%) $-13.60

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.